Farcast Biosciences announced that German TÜV NORD issued ISO 9001 certification for its human Tumor Microdynamics (hTMD) platform, covering TruTumor culturing, pathology, assaying, and data generation technologies.
Farcast Biosciences changed its name to Farcast Biodynamics. The company describes a tumor microenvironment system incorporating perturbation signals, blood-derived peripheral signals, and a biosignature computation model.
Farcast published data in Nature Communications in February 2024 showing pre-detection of patient cohorts responding or resisting nivolumab. Its technology generates biosignatures from multimodal data from live human tumors using proprietary methods and AI models.
Farcast is extending its tumor microenvironment platform with TruPower, which incorporates peripheral markers from patient blood samples to study cancer response without tissue biopsies or surgery.
The privacy policy describes how information is collected, used, and disclosed when users use the service, and outlines privacy rights and legal protections.
